AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
AZ sells ex-US rights to old cancer drugs Arimidex and CasodexFor several years AstraZeneca has been selling off rights to its older drugs to raise cash as it Share XAZ sells ex-US rights to old cancer drugs Arimidex and Casodexhttps://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super Share XMerck & Co’s Keytruda shows promise with prostate cancer ‘super responders’https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/
FDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallThe FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has Share XFDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallhttps://pharmaphorum.com/news/fda-approves-jjs-prostate-cancer-drug-erleada-in-new-use-as-zytiga-sales-fall/
AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
